Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer

Inclusion Criteria: 1. Age ≥18 years old (calculated on the day of signing informed consent); 2. Histologically diagnosed advanced breast cancer, including inoperable locally advanced breast cancer or recurrent/metastatic breast cancer; 3. Immunohistochemical detection of HER-2 (-) or (1+), of which HER-2 (2+) must be tested by FISH and the result is negative; 4. All patients have previously underwent chemotherapy containing anthracyclines and taxanes (adjuvant, neoadjuvant or rescue therapy) , and treatment failure or disease progression received at most two chemotherapy regimens after recurrence/metastasis. HR+/HER2- breast cancer patients need to complete endocrine drug therapy; 5. Physical condition ECOG PS: 0-1; 6. There is at least 1 measurable lesion of metastasis according to RECIST 1.1; 7. The patients voluntarily joined the project and signed the informed consent. Exclusion Criteria: 1. Pregnant or lactating women; 2. Patients with a previous history of breast cancer were excluded, except for ipsilateral DCIS who received only local therapy ≥5 years ago; patients with a history of any other cancer (except non-melanoma skin cancer or cervical carcinoma in situ) were excluded; 3. allergic to Anlotinib; 4. Received eribulin, capecitabine treatment or anti-angiogenic drug treatment in the past; 5. Uncontrolled brain metastases (except asymptomatic, or patients with stable brain metastases receiving local treatment); 6. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.